Meningitis Diagnostic Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2028

 

Meningitis is an infection characterized by inflammation of the meninges. The meninges are the three layers of protective tissue surrounding the neuraxis and consist of the dura mater, arachnoid mater, and pia mater. The central nervous system is represented by neuraxis. Bacteria and viruses are the most common causes of meningitis, and parasites and fungi are less common. Meningitis symptoms include severe headache, vomiting, fever, stiff neck, sensitivity to light, and a distinctive skin rash. Meningitis caused by bacteria is more powerful than meningitis caused by viruses. Meningitis is difficult to diagnose because it exhibits the most common symptoms. Meningitis Diagnostic Testing Market is diagnosed through blood tests that look for the presence of bacteria or viruses that can cause the disease.

Lumbar puncture is another procedure in which cerebrospinal fluid (CSF) is extracted from the base of the spine and tested for bacteria or viruses. Bacterial meningitis is treatable with a cocktail of antibiotics.

Increased R&D activities to diagnose various types of meningitis are expected to drive the Meningitis Diagnostic Testing Market during the forecast period. For example, in July 2018, Antrum Biotech and the University of Cape Town collaborated to develop a new rapid test for tuberculosis (TB) meningitis that can diagnose the disease within two hours. The test is currently being validated for market entry.

Meningitis is an inflammation of the membranes called meninges that surround the brain and spinal cord. My viral, bacterial, parasitic, and fungal infections Meningitis has emerged as a global concern due to its potential to cause an epidemic, and as a result, there is active government support to eradicate meningitis by establishing sophisticated diagnostic centers and hospitals to treat patients. Meningitis Diagnostic Testing Market  is diagnosed using either a rapid latex agglutination test or highly sophisticated equipment for PCR, immunoassays, and other tests.

Key Players

Thermo Fisher Scientific, Inc., BioFire Diagnostics, Siemens, Quest Diagnostics, Bio-Rad Laboratories, Inc., Luminex Corporation, Seegene Inc., IMMY, ELITechGroup, Abbott, Pfizer, Nuron Biotech, GSK, MedImmune, Sanofi, Novartis, Baxter, Merck & Co., Biomed Pvt. Ltd., and others are among the market's key players.